PharmTech spoke with Tara Dougal, event director for pharma at Informa Markets, about trends impacting the pharmaceutical industry and how CPHI Milan is addressing these areas this year.
|Articles|November 1, 2009
- Pharmaceutical Technology-11-02-2009
- Volume 33
- Issue 11
Pharmaceutical Technology, November 2009 Issue (PDF)
Sharing Supply-Chain Security
Advertisement
Articles in this issue
almost 17 years ago
Sharing Supply-Chain Securityalmost 17 years ago
Facing Realityalmost 17 years ago
Changes for Better or Worsealmost 17 years ago
Position Paper: Are We Abandoning IQ and OQ?almost 17 years ago
Safety versus Speed in Drug Developmentalmost 17 years ago
Insider Solutions: A New Direction for USP?almost 17 years ago
DIY Healthcare Reformalmost 17 years ago
Are We Abandoning IQ and OQ?almost 17 years ago
Advancing Chiral Chemistry in API Synthesisalmost 17 years ago
Whatever Happened to Classical Chemistry?Advertisement
Related to this article
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
FDA opens applications for its Expedited IND Pilot, pairing sponsors with qualified research institutions to test rolling CMC review ahead of first-in-human trials.
2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
Karthik Iyer, Eli Lilly, details an AI system linking GMP findings, audits, and deviations for cited, inspection-ready regulatory intelligence.
Advertisement
Advertisement